Biomerica (BMRA) announced that CVS Pharmacy (CVS) has begun in-store sales rollout of the Company’s EZ Detect colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to CVS Health distribution centers in the US, and the product is projected to be on store shelves in September. The Company is also working with CVS Health to introduce an additional Biomerica product to be sold in CVS pharmacies. “We’re excited to broaden the distribution of EZ Detect in the US,” commented Zack Irani, CEO of Biomerica. “CVS Pharmacy is the largest Pharmacy system in the USA. Each day, approximately 5 million customers visit a CVS Pharmacy. Early detection is a key factor to beating colorectal cancer. The inclusion of EZ Detect(TM) on CVS Pharmacy shelves is a significant development in making our easy and innovative in-home tests available to more patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRA:
- CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test
- Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
- Biomerica receives notice of patent allowance in China for potential technology
